Literature DB >> 30685614

Establishment and characterization of an iPSC line (FRIMOi001-A) derived from a retinitis pigmentosa patient carrying PDE6A mutations.

Marina Riera1, Achchhe Patel2, Borja Corcostegui3, Stanley Chang4, Janet R Sparrow4, Esther Pomares5, Barbara Corneo2.   

Abstract

Retinitis pigmentosa (RP) refers to a clinical and genetic heterogeneous group of inherited retinal degenerations characterized by photoreceptor cell death. In this work, we have generated an induced pluripotent stem cell (iPSC) line derived from a RP patient with two heterozygous mutations in the cGMP-specific phosphodiesterase 6A alpha subunit (PDE6A) gene. Skin fibroblasts were generated and reprogrammed by using a Sendai virus-based approach. The iPSC line had a normal karyotype, carried the two PDE6A mutations, expressed pluripotency markers and could generate endoderm, mesoderm and ectoderm in vitro. Resource table.
Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30685614     DOI: 10.1016/j.scr.2019.101385

Source DB:  PubMed          Journal:  Stem Cell Res        ISSN: 1873-5061            Impact factor:   2.020


  2 in total

Review 1.  Stem cell transplantation as a progressing treatment for retinitis pigmentosa.

Authors:  Sedighe Hosseini Shabanan; Homa Seyedmirzaei; Alona Barnea; Sara Hanaei; Nima Rezaei
Journal:  Cell Tissue Res       Date:  2022-01-10       Impact factor: 5.249

2.  Evaluation of photoreceptor-directed fibroblasts derived from retinitis pigmentosa patients with defects in the EYS gene: a possible cost-effective cellular model for mechanism-oriented drug.

Authors:  Dilip Rai; Masaki Iwanami; Yoriko Takahashi; Yukari Komuta; Noriyuki Aoi; Akihiro Umezawa; Yuko Seko
Journal:  Stem Cell Res Ther       Date:  2022-04-11       Impact factor: 6.832

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.